Literature DB >> 32076827

RELINF: prospective epidemiological registry of lymphoid neoplasms in Spain. A project from the GELTAMO group.

Mariana Bastos-Oreiro1,2, Ana Muntañola3, Carlos Panizo4, Eva Gonzalez-Barca5, Sonia González de Villambrosia6, Raúl Córdoba7, Jose Luís Bello López8, Pedro González-Sierra9, María José Terol10, Antonio Gutierrez11, Carlos Grande12, María José Ramirez13, Laura Iserte14, Elena Perez15, Belén Navarro16, Pilar Gomez17, Antonio Salar18, Hugo Luzardo19, Andrés López20, Raquel Del Campo21, Daniel García-Belmonte22, María Jesús Vida23, María Infante24, Jose Antonio Queizan-Hernandez25, Silvana Novelli26, Miriam Moreno27, Miriam Penarrubia28, Joaquín Gómez29, Abel Domingo30, Eva Donato31, María Cruz Viguria32, Francisca López33, María José Rodriguez34, Emilia Pardal35, Victor Noriega36, Rafael Andreu37, Javier Peñalver38, Alejandro Martín39, Dolores Caballero39, Armando López-Guillermo40.   

Abstract

Lymphomas are a large, heterogeneous group of neoplasms with well-defined characteristics, and this heterogeneity highlights the importance of epidemiological data. Knowledge of local epidemiology is essential to optimise resources, design clinical trials, and identify minority entities. Given there are few published epidemiological data on lymphoma in Spain, the Spanish Lymphoma and Autologous Bone Marrow Transplant Group created the RELINF project. The aim of this project is to determine the frequencies and distribution of lymphoid neoplasms in Spain and to analyse survival. We developed an online platform for the prospective collection of data on newly diagnosed cases of lymphoma in Spain between January 2014 and July 2018; 11,400 patients were registered. Diffuse large B cell lymphoma (DLBCL) and follicular lymphoma (FL) were the most frequent lymphomas in our series. Marginal B cell lymphoma frequency was higher than that reported in other studies, representing more than 11% of mature B cell lymphomas. Peripheral T cell lymphoma not otherwise specified (PTCL-NOS) was the most common subtype of T cell lymphoma, and NK/T cell lymphomas were more frequent than expected (5.4% of total). Hodgkin's lymphoma accounted for 12% of lymphoproliferative syndromes. Overall survival was greater than 90% at 2 years for indolent B cell lymphomas, and approximately 60% for DLBCL, somewhat lower than that previously reported. Survival was poor for PTCL-NOS and angioimmunoblastic T cell lymphoma, as expected; however, it was somewhat better than that in other studies for anaplastic large cell anaplastic lymphoma kinase lymphomas. This is the first prospective registry to report the frequencies, distribution, and survival of lymphomas in Spain. The frequencies and survival data we report here are globally consistent with that reported in other Western countries. These updated frequencies and survival statistics are necessary for developing appropriate management strategies for neoplasias in the Spanish population.

Entities:  

Keywords:  Epidemiology; Frequencies; Lymphoma; Survival

Year:  2020        PMID: 32076827     DOI: 10.1007/s00277-020-03918-6

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  6 in total

1.  Risk Factors and Mortality of COVID-19 in Patients With Lymphoma: A Multicenter Study.

Authors:  Isabel Regalado-Artamendi; Ana Jiménez-Ubieto; José Ángel Hernández-Rivas; Belén Navarro; Lucía Núñez; Concha Alaez; Raúl Córdoba; Francisco Javier Peñalver; Jimena Cannata; Pablo Estival; Keina Quiroz-Cervantes; Rosalía Riaza Grau; Alberto Velasco; Rafael Martos; Amalia Domingo-González; Laurentino Benito-Parra; Elvira Gómez-Sanz; Javier López-Jiménez; Arturo Matilla; María Regina Herraez; María José Penalva; Julio García-Suárez; José Luis Díez-Martín; Mariana Bastos-Oreiro
Journal:  Hemasphere       Date:  2021-02-10

2.  Incorporation of next-generation sequencing in clinical practice using solid and liquid biopsy for patients with non-Hodgkin's lymphoma.

Authors:  Mariana Bastos-Oreiro; Julia Suárez-González; Ismael Buño; Carolina Martínez-Laperche; Cristina Andrés-Zayas; Natalia Carolina Carrión; Solsiré Moreno; Diego Carbonell; María Chicano; Paula Muñiz; Laura Sanz; Francisco Javier Diaz-Crespo; Javier Menarguez; José Luis Diez-Martín
Journal:  Sci Rep       Date:  2021-11-24       Impact factor: 4.379

3.  Survival and Epidemiologic Trends of Lymphomas in Saudi Arabia: A 10-Year Report from a Tertiary Care Hospital.

Authors:  Mashael Yahya Altowairqi; Mohammed Yousef Alyousef; Mohammed Khaled Ghandour; Abdulrahman Abdulmohsen Alrashed; Yousef Jebrin Aljebrin; Ghadah Abdulkarim Alotheem; Aamer Aleem; Farjah Algahtani; Musa F Alzahrani
Journal:  Saudi J Med Med Sci       Date:  2022-01-12

4.  Cost-Effectiveness Analysis of Axicabtagene Ciloleucel vs. Tisagenlecleucel for the Management of Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Spain.

Authors:  Mariana Bastos-Oreiro; Ana de Las Heras; María Presa; Miguel A Casado; Carlos Pardo; Victoria Martín-Escudero; Anna Sureda
Journal:  Cancers (Basel)       Date:  2022-01-21       Impact factor: 6.639

5.  Best Treatment Option for Patients With Refractory Aggressive B-Cell Lymphoma in the CAR-T Cell Era: Real-World Evidence From GELTAMO/GETH Spanish Groups.

Authors:  Mariana Bastos-Oreiro; Antonio Gutierrez; Juan Luís Reguera; Gloria Iacoboni; Lucía López-Corral; María José Terol; Valentín Ortíz-Maldonado; Jaime Sanz; Luisa Guerra-Dominguez; Rebeca Bailen; Alberto Mussetti; Pau Abrisqueta; Rafael Hernani; Hugo Luzardo; Juan-Manuel Sancho; Javier Delgado-Serrano; Antonio Salar; Carlos Grande; Leyre Bento; Sonia González de Villambrosía; Daniel García-Belmonte; Anna Sureda; Antonio Pérez-Martínez; Pere Barba; Mi Kwon; Alejandro Martín García-Sancho
Journal:  Front Immunol       Date:  2022-07-12       Impact factor: 8.786

6.  EZH2 mutations at diagnosis in follicular lymphoma: a promising biomarker to guide frontline treatment.

Authors:  C Martínez-Laperche; L Sanz-Villanueva; F J Díaz Crespo; P Muñiz; R Martín Rojas; D Carbonell; M Chicano; J Suárez-González; J Menárguez; M Kwon; J L Diez Martín; I Buño; M Bastos Oreiro
Journal:  BMC Cancer       Date:  2022-09-14       Impact factor: 4.638

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.